Silence Therapeutics PLC New divisional patent and injunction application (4886D)
October 10 2018 - 2:00AM
UK Regulatory
TIDMSLN
RNS Number : 4886D
Silence Therapeutics PLC
10 October 2018
Silence Therapeutics Announces Receipt of a New European Notice
of Intention to Grant a Patent and the Launch of an Interim
European Injunction Application against Onpattro(TM)
October 10 2018
LONDON, Silence Therapeutics plc, (LON:SLN) ("Silence" or "the
Company") a leader in the discovery, development and delivery of
novel RNA therapeutics for the treatment of serious diseases,
confirms the receipt of a notice of intention to grant for a new
European divisional patent, EP 3 222 724B, and further said that it
has commenced a new cross-border interim injunction application in
the Netherlands against Alnylam's Onpattro(TM) (patisiran).
Silence received a notice of intention to grant from the
European Patent Office for patent application EP 3 222 724B,
further strengthening its innovative chemical modification
technology patent family in Europe, which sits at the heart of the
current therapeutic siRNA field.
Silence has further filed a cross-border interim injunction
application in the Netherlands (where Alnylam holds its Marketing
Authorisation for Onpattro(TM)), requesting the courts to prohibit
Alnylam from commercialising Onpattro(TM) across Europe until the
resolution of the trial to determine infringement of EP 3 222 724B
by Onpattro(TM). Despite requests not to do so, Alnylam has openly
commercialised Onpattro(TM) in the face of the Silence claims. The
Company therefore feels that it has been left with no alternative
other than to take the necessary steps to enforce its patents and
protect the historic investment made in its technology.
Onpattro(TM) remains accused of infringement of Silence European
Patent EP 1 847 547B in the United Kingdom and Portugal and Silence
is seeking injunctive relief in these territories to restrain
Alnylam's infringement. The UK trial is to be held in December
2018, with a decision expected in early 2019. While Silence
continues to protect its rights and inventions, the Company remains
focused on executing its core business of drug discovery and
development to continue to build its therapeutic pipeline.
David Horn Solomon, Chief Executive Officer of Silence
Therapeutics, commented:
"Silence continues to innovate with new, competitive RNAi
medicines. During 2017 & 2018, the European Patent Office has
upheld the validity of our expanding patent estate with the
granting of additional patents around our foundational chemical
modification IP.
When companies openly promote new product commercialisation in
the face of relevant granted patent rights, Silence Therapeutics
will take steps to enforce its patents and protect the historic
investment made in its technology."
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20 3457
Dr David Horn Solomon, Chief Executive 6900
Officer
David Ellam, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Broker) Tel: +44 (0)20 7418
James Steel/Oliver Jackson 8900
European IR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott / Angela Gray
silencetherapeutics@consilium-comms.com
US IR Tel: +1 (212) 213-0006
Burns McClellan
Lisa Burns, Jill Steier, John Grimaldi
Silence.therapeutics@burnsmc.com
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural
mechanism of RNA interference, or RNAi, within its cells. Its
proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using
its enabling delivery systems, it has achieved an additional
level of specificity by delivering its
therapeutic RNA molecules exclusively to target cells. Silence's
proprietary RNA chemistries and
delivery systems are designed to improve the stability of our
molecules and enhance effective delivery
to target cells, providing a powerful modular technology well
suited to tackle life-threatening diseases.
For more information, please visit:
https://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCUGGWCUUPRPUB
(END) Dow Jones Newswires
October 10, 2018 02:00 ET (06:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2023 to Apr 2024